Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Identification of Protein That Helps Coronavirus Spread through Cells Could Help Develop COVID-19 Treatment

By HospiMedica International staff writers
Posted on 19 Aug 2020
Biochemistry and molecular biology researchers at the Colorado State University (Fort Collins, CO, USA) have identified a protein encoded by SARS-CoV-2 that may be associated with the quick spread of the virus through cells in the human body.

Through powerful application of the foundational sciences and bioinformatic analysis their research highlights key characteristics of the virus that could one day be important in the development of a treatment for COVID-19. More...
Before COVID-19, the researchers had been studying prions - misfolded proteins that can transmit their abnormal shape onto normal variants of the same protein. Prions cause several fatal and transmissible neurodegenerative diseases, including Mad Cow Disease in cattle and Creutzfeldt-Jakob disease in humans.

Cascarina’s sub-focus has been on low-complexity domains - regions in a protein’s sequence that differ from typical regions in their amino acid composition and chemical behavior. What makes these low-complexity protein domains interesting is their tendency toward liquid-liquid phase separation, similar to oil separating from water. Some of these proteins form “biomolecular condensates” in a cell, which are small areas in a cell where the protein is highly-concentrated, analogous to the oil droplets that form when oil separates from water.

When the researchers pivoted to study COVID-19 earlier this year, they found that the nucleocapsid, or N, protein in the SARS-CoV-2 virus has a low-complexity domain that may utilize liquid-liquid phase separation to facilitate the packaging of viral RNA into new virus particles that can infect neighboring cells. The N protein may also be associated with reducing an infected cell’s anti-viral stress response. Cells often form something called stress granules, a type of biomolecular condensate, to respond to a change in their environment, and these granules may have an anti-viral effect. The application of this research could be for the development of treatments once a person has already contracted the virus, rather than preventing infection like a vaccine. Both of these areas of research are essential to slowing and ending the COVID-19 pandemic.

“Medically, if you could counteract the virus’ ability to interfere with a cell’s immune response, then you could help the cells to fight off the virus,” said biochemistry researcher Eric Ross. “I think this falls into the category of very basic science: if we understand the viral process, then conceivably we can try to design a drug that reverses that process.”

Related Links:

Colorado State University


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.